Viking Therapeutics Unveils Positive Results from Phase 2 Trial of VK2735 Tablet for Obesity, Showing Significant Weight Loss
Reuters
Aug 19
<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Positive Results from Phase 2 Trial of VK2735 Tablet for Obesity, Showing Significant Weight Loss
Viking Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of the VK2735 tablet formulation in patients with obesity. The trial achieved its primary and secondary endpoints, demonstrating statistically significant reductions in body weight with once-daily dosing of VK2735 compared to placebo. Patients treated with VK2735 experienced an average weight loss of up to 12.2% after 13 weeks, whereas the placebo group showed a 1.3% weight loss. VK2735 was found to be safe and well-tolerated, with 99% of gastrointestinal-specific adverse events considered mild or moderate. The results have been presented and discussed in a scheduled conference call.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA54249) on August 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.